(Reuters) -Cassava Sciences said it will stop all trials of its Alzheimer's disease drug after it failed a late-stage study, ...

Inc. (NASDAQ: SAVA) witnessed a dramatic over 85% plunge in its stock price following the release of disappointing results ...

Cassava Sciences' Phase 3 trial for Alzheimer's failed to meet primary or secondary endpoints, leading to the discontinuation ...

The Cassava Sciences story ended Monday exactly as many knew it would — with the company’s experimental drug for Alzheimer’s ...

Cassava Sciences' Alzheimer's drug simufilam failed its Phase 3 trial and the stock plummeted ~90%. See why I changed my ...

Cassava Sciences stock plummeted Monday after the company's Alzheimer's treatment failed in Phase 3 testing. Roche's Proposed ...

Cassava Sciences shares are plunging in premarket trading and are losing most of their value after the biotech firm said its ...

NEW YORK, NY / ACCESSWIRE / November 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava ...

Cassava Sciences’ phase 3 Alzheimer’s disease trial has missed its co-primary endpoints. With the study also missing ...

Cassava Sciences has revealed the late-stage clinical failure of controversial Alzheimer’s drug simulfilam. The company had ...

Research analysts at HC Wainwright decreased their FY2024 earnings estimates for shares of Cassava Sciences in a research report issued on Tuesday, November 26th. HC Wainwright analyst V. Bernardino ...

Shares in the pharmaceutical company fell a staggering 85% on Monday after it reported disappointing Phase 3 results.